Literature DB >> 24778011

Bone morphogenetic protein-focused strategies to induce cytotoxicity in lung cancer cells.

Anastasios Fotinos1, Narayani Nagarajan, Adriano S Martins, David T Fritz, Diane Garsetti, Annette T Lee, Charles C Hong, Melissa B Rogers.   

Abstract

BACKGROUND: High bone morphogenetic protein (BMP)-2 expression in lung carcinoma correlates with poor patient prognosis. The present study explored strategies to repress BMP signaling.
MATERIALS AND METHODS: The cytotoxicity of BMP2-knockdown, dorsomorphin derivatives, and microRNAs was tested in transformed and non-transformed lung cells. Microarray analyses of 1,145 microRNAs in A549 lung adenocarcinoma cells and two other transformed lung cell types relative to BEAS-2B bronchial epithelial cells were performed.
RESULTS: Reduced BMP2 synthesis inhibited A549 cell growth. The dorsomorphin derivative LDN-193189, but not DMH1 or DMH4, was strongly cytotoxic towards A549 cells, but not towards BEAS-2B cells. Microarray analysis revealed that 106 miRNAs were down-regulated and 69 miRNAs were up-regulated in the three transformed lines. Three down-regulated miRNAs, hsa-mir-34b, hsa-mir-34c-3p, and hsa-miR-486-3p, repressed a BMP2 reporter gene and were cytotoxic in A549 cells, but not towards BEAS-2B cells.
CONCLUSION: The observed cytotoxicity suggests that reducing BMP signaling is a useful line of attack for therapy of lung cancer.

Entities:  

Keywords:  Bone morphogenetic proteins; RNA interference; cell proliferation; cell survival; lung neoplasms; microRNAs; preclinical drug evaluation

Mesh:

Substances:

Year:  2014        PMID: 24778011      PMCID: PMC4791537     

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  37 in total

1.  Type beta transforming growth factor: a bifunctional regulator of cellular growth.

Authors:  A B Roberts; M A Anzano; L M Wakefield; N S Roche; D F Stern; M B Sporn
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

2.  Involvement of microRNA in AU-rich element-mediated mRNA instability.

Authors:  Qing Jing; Shuang Huang; Sabine Guth; Tyler Zarubin; Andrea Motoyama; Jianming Chen; Franco Di Padova; Sheng-Cai Lin; Hermann Gram; Jiahuai Han
Journal:  Cell       Date:  2005-03-11       Impact factor: 41.582

3.  A continuous tumor-cell line from a human lung carcinoma with properties of type II alveolar epithelial cells.

Authors:  M Lieber; B Smith; A Szakal; W Nelson-Rees; G Todaro
Journal:  Int J Cancer       Date:  1976-01-15       Impact factor: 7.396

4.  The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells.

Authors:  Elaine M Langenfeld; Steve E Calvano; Fadi Abou-Nukta; Stephen F Lowry; Peter Amenta; John Langenfeld
Journal:  Carcinogenesis       Date:  2003-06-19       Impact factor: 4.944

5.  Gene-expression profiles predict survival of patients with lung adenocarcinoma.

Authors:  David G Beer; Sharon L R Kardia; Chiang-Ching Huang; Thomas J Giordano; Albert M Levin; David E Misek; Lin Lin; Guoan Chen; Tarek G Gharib; Dafydd G Thomas; Michelle L Lizyness; Rork Kuick; Satoru Hayasaka; Jeremy M G Taylor; Mark D Iannettoni; Mark B Orringer; Samir Hanash
Journal:  Nat Med       Date:  2002-07-15       Impact factor: 53.440

6.  Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors.

Authors:  Elaine M Langenfeld; John Langenfeld
Journal:  Mol Cancer Res       Date:  2004-03       Impact factor: 5.852

7.  SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.

Authors:  Gareth J Inman; Francisco J Nicolás; James F Callahan; John D Harling; Laramie M Gaster; Alastair D Reith; Nicholas J Laping; Caroline S Hill
Journal:  Mol Pharmacol       Date:  2002-07       Impact factor: 4.436

8.  A rapid and convenient assay for counting cells cultured in microwell plates: application for assessment of growth factors.

Authors:  M H Oliver; N K Harrison; J E Bishop; P J Cole; G J Laurent
Journal:  J Cell Sci       Date:  1989-03       Impact factor: 5.285

9.  Bone morphogenetic protein receptor signaling is necessary for normal murine postnatal bone formation.

Authors:  Ming Zhao; Stephen E Harris; Diane Horn; Zhaopo Geng; Riko Nishimura; Gregory R Mundy; Di Chen
Journal:  J Cell Biol       Date:  2002-06-10       Impact factor: 10.539

10.  Small molecule antagonist of the bone morphogenetic protein type I receptors suppresses growth and expression of Id1 and Id3 in lung cancer cells expressing Oct4 or nestin.

Authors:  Elaine Langenfeld; Malik Deen; Emmanuel Zachariah; John Langenfeld
Journal:  Mol Cancer       Date:  2013-10-26       Impact factor: 27.401

View more
  16 in total

1.  Characterization of new bone morphogenetic protein (Bmp)-2 regulatory alleles.

Authors:  Tapan A Shah; Youhua Zhu; Nadia N Shaikh; Marie A Harris; Stephen E Harris; Melissa B Rogers
Journal:  Genesis       Date:  2017-05-22       Impact factor: 2.487

2.  Inhibition of bone morphogenetic protein signaling reduces viability, growth and migratory potential of non-small cell lung carcinoma cells.

Authors:  Jelena Mihajlović; Laura A M Diehl; Andreas Hochhaus; Joachim H Clement
Journal:  J Cancer Res Clin Oncol       Date:  2019-09-17       Impact factor: 4.553

Review 3.  Calcific aortic valve disease: a consensus summary from the Alliance of Investigators on Calcific Aortic Valve Disease.

Authors:  Katherine E Yutzey; Linda L Demer; Simon C Body; Gordon S Huggins; Dwight A Towler; Cecilia M Giachelli; Marion A Hofmann-Bowman; Douglas P Mortlock; Melissa B Rogers; Mehran M Sadeghi; Elena Aikawa
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-09-04       Impact factor: 8.311

Review 4.  Turning Bone Morphogenetic Protein 2 (BMP2) on and off in Mesenchymal Cells.

Authors:  Melissa B Rogers; Tapan A Shah; Nadia N Shaikh
Journal:  J Cell Biochem       Date:  2015-10       Impact factor: 4.429

Review 5.  Emerging roles of the bone morphogenetic protein pathway in cancer: potential therapeutic target for kinase inhibition.

Authors:  Pawina Jiramongkolchai; Philip Owens; Charles C Hong
Journal:  Biochem Soc Trans       Date:  2016-08-15       Impact factor: 5.407

6.  Competing Repressive Factors Control Bone Morphogenetic Protein 2 (BMP2) in Mesenchymal Cells.

Authors:  Anastasios Fotinos; David T Fritz; Steven Lisica; Yijun Liu; Melissa B Rogers
Journal:  J Cell Biochem       Date:  2016-02       Impact factor: 4.429

7.  miR-486 Promotes the Invasion and Cell Cycle Progression of Ovarian Cancer Cells by Targeting CADM1.

Authors:  Chenyang Li; Yue Wang; Hao Wang; Bowen Wang; Yunxia Wang; Nan Li; Yanli Qin; Yesheng Wang
Journal:  Anal Cell Pathol (Amst)       Date:  2021-08-05       Impact factor: 2.916

8.  A role for BMP-induced homeobox gene MIXL1 in acute myelogenous leukemia and identification of type I BMP receptor as a potential target for therapy.

Authors:  Aaron Raymond; Bin Liu; Hong Liang; Caimiao Wei; Michele Guindani; Yue Lu; Shoudan Liang; Lisa S St John; Jeff Molldrem; Lalitha Nagarajan
Journal:  Oncotarget       Date:  2014-12-30

Review 9.  Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2.

Authors:  Eleanor Williams; Alex N Bullock
Journal:  Bone       Date:  2017-09-12       Impact factor: 4.398

10.  Sjögren's syndrome-associated microRNAs in CD14(+) monocytes unveils targeted TGFβ signaling.

Authors:  Adrienne E G Williams; Kevin Choi; Annie L Chan; Yun Jong Lee; Westley H Reeves; Michael R Bubb; Carol M Stewart; Seunghee Cha
Journal:  Arthritis Res Ther       Date:  2016-05-03       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.